Cet anticorps anti-RSV (Palivizumab Biosimilar) est un anticorps Humanized Monoclonal détectant RSV (Palivizumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.
N° du produit ABIN7200664
Aperçu rapide pour Recombinant RSV (Palivizumab Biosimilar) anticorps (ABIN7200664)
Antigène
RSV (Palivizumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp RSV (Palivizumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Fonction
Palivizumab Biosimilar, RSV Monoclonal Antibody
Specificité
The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
Attributs du produit
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method
Immunogène
The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Stock
4°C,-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.